HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Askanas, V. Articles by Engel, W. K. Search for Related Content PubMed PubMed Citation Articles by Askanas, V. Articles by Engel, W. K.

CSF from amyotrophic lateral sclerosis patients applied to motor neurons in culture fails to alter neuron-specific enolase

Neuromuscular Diseases Section (Drs. Askanas and Engel), National Institute of Neurological and Communicative Disorders and Stroke, and the Laboratory of clinical Science (Dr. Marangos), National Institute of Mental Health, Bethesda, MD.

Immunoreactivity of neuron-specific enolase was measured in cultured embryonic rat motor neurons as an index of neuronal health. Treatment with cerebrospinal fluid from patients with amyotrophic lateral sclerosis and other neuromuscular disorders had no effect on neuron-specific enolase.

Address correspondence and reprint requests to Dr. Askanas, Center for Neuromuscular Diseases, Department of Neurology, USC School of Medicine, Hospital of the Good Samaritan, 616 S. Witmer Street, Los Angeles, CA 90017.

This work was supported in part by the Muscular Dystrophy Association of America.

Accepted for publication November 20. 1980.

This article has been cited by other articles:

				H. Mitsumoto, M. R. Hanson, and D. A. Chad Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials Arch Neurol, February 1, 1988; 45(2): 189 - 202. [Abstract] [PDF]